Trials / Completed
CompletedNCT00242749
IRESSA in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma
A Phase 2 Trial to Evaluate ZD1839 (IRESSA) in Combination With Cisplatin & Radiotherapy in Patients With Advanced Head & Neck Carcinoma (Unresectable &Inoperable)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
· To evaluate the disease free survival rate at 2 years of patients with advanced head and neck carcinoma treated with ZD1839 250 mg administered once daily in combination with cisplatin and a standard course of radiotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gefitinib, Cisplatin and Radiotherapy |
Timeline
- Start date
- 2002-12-01
- Completion
- 2007-07-01
- First posted
- 2005-10-21
- Last updated
- 2009-04-23
Locations
4 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT00242749. Inclusion in this directory is not an endorsement.